Time period given by analyst is six months when Amrutanjan Health Care Ltd. price can reach defined target.
Amrutanjan Health Care Ltd., incorporated in the year 1936, is a Small Cap company (having a market cap of Rs 2454.64 Crore) operating in Pharmaceuticals sector.
Amrutanjan Health Care Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap, Raw Materials for the year ending 31-Mar-2020.
Financials
For the quarter ended 30-06-2021, the company reported a Standalone Total Income of Rs 80.95 Crore, down -16.29 % from last quarter Total Income of Rs 96.70 Crore and up 66.35 % from last year same quarter Total Income of Rs 48.66 Crore. Company reported net profit after tax of Rs 12.06 Crore in latest quarter.
Investment Rationale
AHCL’s earnings grew at a CAGR 17% FY17-21. Going forward, the brokerage is positive on the future growth prospects and expect AHCL to be ahead of the category performance mainly in the OTC segment. AHCL’s revenue and PAT is likely to record a growth of 17.5% and 16.7% CAGR over FY21-23E. Along with this the brokerage expects the company to generate consistent FCF with consistent high ROEs. The Comfy brand is expected to be the key growth driver for AHCL. It expects, “Comfy” revenues to grow at CAGR 28% while other OTC products are expected to grow at CAGR 13.2% over FY21-23E. Though AHCL is in branded personal are segment, it may not get the valuations that other FMCG players get due to its single brand and single segment concentration, though it has been working to diversify that and has succeeded to some extent so far. However the brokerage feels that there is a scope for some upward valuation re-rating in the stock currently.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
